2019
home
December
About
There are trials that indicate that Aducanumab may - after initially negative results - slow down Alzheimer's disease if applied in high doses. More research is needed.
Contact: info@neat-news.com. neat-news.com is not responsible for the content of external sites. We do not link to external sites in return for money or any other benefits. The page is maintained in Germany and for any legal matters the laws of Germany apply. neat-news.com © 2019.